Edition:
United States

Akankshita Mukhopadhyay

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

May 04 2018

Celgene profit tops estimates; clarifies path for key MS drug

Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

May 01 2018

Pfizer first-quarter results miss estimates as key drug sales fall short

NEW YORK Pfizer Inc on Tuesday reported lower-than-expected first-quarter revenue as demand for some key drugs and international sales fell short of estimates, sparking a 5.1 percent drop in shares of the largest U.S. drugmaker. | Video

Apr 25 2018

LabCorp's Covance business powers quarterly profit beat; shares rise

Laboratory Corp of America Holdings posted a quarterly profit on Wednesday that beat analysts' estimates, helped by higher demand at the unit performing clinical trials for drugmakers, and prompting the company to raise its full-year revenue target.

Mar 15 2018

Alexion's second rare blood disorder drug could fortify future revenue

Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms.

Mar 05 2018

Dermira to abandon acne drug, shares crater

Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.

Mar 02 2018

Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta

Biogen Inc and AbbVie Inc have withdrawn their multiple sclerosis drug, the companies said on Friday, following reports of eight cases of inflammation of the brain, prompting the European Medicines Agency (EMA) to start an urgent review.

Feb 27 2018

Generic drugmaker Endo 2018 forecast disappoints, shares drop

Endo International Plc's full-year revenue and profit forecasts fell short of Street estimates, due to continued pressure on its generics business and increased competition, sending its shares down nearly 5 percent in on Tuesday.

Jan 25 2018

Bluebird CAR-T still top Celgene priority after Juno deal

Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio .

Dec 26 2017

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

Dec 07 2017

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary